(1r,4r)-4-(氨基甲基)环己烷羧酸乙酯 | 19878-18-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (1r,4r)-4-(氨基甲基)环己烷羧酸乙酯
• 中文别名: 反式-4-(氨基甲基)环己烷羧酸盐酸盐
• 英文名称: 4-(aminomethyl)cyclohexanecarboxylic acid ethyl ester hydrochloride
• 英文别名: ethyl 4-aminomethylcyclohexylcarboxylate hydrochloride；trans-Ethyl 4-(aminomethyl)cyclohexanecarboxylate hydrochloride；ethyl 4-(aminomethyl)cyclohexane-1-carboxylate;hydrochloride
• CAS: 19878-18-3
• 化学式: C₁₀H₁₉NO₂*ClH
• 分子量: 221.727
• InChiKey: ZGOGVHCRASZRFV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.74
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  52.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  (1r,4r)-4-(氨基甲基)环己烷羧酸乙酯 在 sodium carbonate 作用下， 以 水 为溶剂， 反应 6.0h， 以89%的产率得到tranexamic acid
  参考文献：
  名称：

  一种合成氨甲环酸的方法

  摘要：

  本发明公开了一种氨甲环酸(I)的合成工艺，包括如下步骤：以3‑环己烯甲酸(V)为原料，通过酯化反应得到中间体3‑环己烯甲酸酯(IV)；中间体(IV)在催化剂的存在下与一氧化碳/氢气混合气体或者合成气发生插羰反应，高选择性得到中间体4‑甲酰基环己烷‑1‑甲酸酯(III)；中间体(III)再通过还原胺化得到中间体4‑氨甲基环己烷甲酸酯(II)；中间体(II)最后水解、转型，即可得到氨甲环酸(I)。本发明原料便宜易得，一氧化碳插羰反应绿色环保，路线简洁高效，为氨甲环酸(I)的合成提供了新方法。

  公开号：

  CN114181077A
• 作为产物：
  描述：

  (1r,4r)-乙基 4-甲酰基环己烷羧酸 在 氨 、 palladium on activated charcoal 、 氢气 、 盐酸 作用下， 以 乙醇 、 甲基叔丁基醚 为溶剂， 20.0~80.0 ℃ 、1.0 MPa 条件下， 反应 8.0h， 以92.4%的产率得到(1r,4r)-4-(氨基甲基)环己烷羧酸乙酯
  参考文献：
  名称：

  一种合成氨甲环酸的方法

  摘要：

  本发明公开了一种氨甲环酸(I)的合成工艺，包括如下步骤：以3‑环己烯甲酸(V)为原料，通过酯化反应得到中间体3‑环己烯甲酸酯(IV)；中间体(IV)在催化剂的存在下与一氧化碳/氢气混合气体或者合成气发生插羰反应，高选择性得到中间体4‑甲酰基环己烷‑1‑甲酸酯(III)；中间体(III)再通过还原胺化得到中间体4‑氨甲基环己烷甲酸酯(II)；中间体(II)最后水解、转型，即可得到氨甲环酸(I)。本发明原料便宜易得，一氧化碳插羰反应绿色环保，路线简洁高效，为氨甲环酸(I)的合成提供了新方法。

  公开号：

  CN114181077A

文献信息

• OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF
  申请人：Hahn Michael

  公开号：US20110034450A1

  公开（公告）日：2011-02-10

  The present application relates to novel carboxylic acid derivatives having an oxo-substituted azaheterocyclic partial structure, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prevention of cardiovascular disorders.

  本申请涉及具有氧代取代的氮杂杂环部分结构的新型羧酸衍生物，其制备方法，其用于治疗和/或预防疾病的用途，以及其用于生产用于治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防心血管疾病的用途。
• Nicotinamide derivatives
  申请人：Pfizer Inc

  公开号：US06380218B1

  公开（公告）日：2002-04-30

  A compound of formula (I) wherein m, n, o, p, q, r, A, B, D, E, R1, R2,R3, R4, R5, R6, R7 and R8 are as defined in the description, useful in the treatment of respiratory, allergic, rheumatoid, body weight regulation, inflammatory and central nervous system disorders such as asthma, chronic obstructive pulmonary disease, adult respiratory diseases syndrome, shock, fibrosis, pulmonary hypersensitivity, allergic rhinitis, atopic dermatitis, psoriasis, weight control, rheumatoid arthritis, cachexia, crohn's disease, ulcerative colitis, arthritic conditions and other inflammatory diseases, depression, multi-infarct dementia and AIDS.

  化合物式(I)中，m、n、o、p、q、r、A、B、D、E、R1、R2、R3、R4、R5、R6、R7和R8如描述中所定义，可用于治疗呼吸系统、过敏、风湿性、体重调节、炎症和中枢神经系统疾病，如哮喘、慢性阻塞性肺病、成人呼吸系统疾病综合征、休克、纤维化、肺过敏、过敏性鼻炎、特应性皮炎、银屑病、体重控制、类风湿性关节炎、消瘦症、克罗恩病、溃疡性结肠炎、关节炎和其他炎症性疾病、抑郁症、多发性梗塞性痴呆和艾滋病。
• 4-(Aminomethyl)cyclohexane-1-carboxylic acid derivatives
  申请人：KUREHA KAGAKU KOGYO KABUSHIKI KAISHA

  公开号：EP0055145A1

  公开（公告）日：1982-06-30

  4-[N-(3',4'-Methylenedioxybenzylidene) amino-methyl]-cyclohexane-1-carboxylic acid, or a pharmaceutically acceptable salt or a C1-C4 alkyl ester thereof, are useful for the treatment of inflammation, thrombosis, hypertension, asthma, cancer, rheumatism or systemic lupus erythematosus. These compounds can be formulated into pharmaceutical compositions and are prepared by reacting 3,4-methylene-dioxybenzaldehyde with 4-aminomethylcyclohexane-1-carboxylic acid or a C1-C4 alkyl ester thereof, and optionally converting the resulting compound into a pharmaceutically acceptable salt.

  4-[N-(3',4'-亚甲二氧基苄基)氨基甲基]-环己烷-1-羧酸或其药学上可接受的盐或 C1-C4 烷基酯可用于治疗炎症、血栓、高血压、哮喘、癌症、风湿病或系统性红斑狼疮。这些化合物可配制成药物组合物，其制备方法是将 3,4-亚甲基二氧基苯甲醛与 4-氨基甲基环己烷-1-羧酸或其 C1-C4 烷基酯反应，并将所得化合物转化为药学上可接受的盐。
• MRI CONTRAST AGENT HAVING GADOLINIUM COMPLEX
  申请人：Kyungpook National University Industry- Academic Cooperation Foundation

  公开号：EP2623500A1

  公开（公告）日：2013-08-07

  The present invention relates to a magnetic resonance imaging (MRI) contrast agent including a gadolinium complex, more particularly to a DO3A-tranexamic acid or its ester compound, which is represented by the Chemical Formula 1. A DO3A-tranexamic acid or its ester compound may be prepared according to the present invention and a gadolinium complex may be prepared using the compound. An MRI contrast agent including the gadolinium complex prepared according to the present invention as an active ingredient has higher relaxivity as compared to the currently commercially available contrast agent. In addition, the MRI contrast agent according to the present invention has bifunctionality of liver-specific and blood-pool contrasting effect. Accordingly, since the MRI contrast agent including the gadolinium complex according to the present invention satisfies the key properties required for a contrast agent for MRI, it can be widely used as an MRI contrast agent and can provide enhanced contrasting effect as compared to the existing contrast agent.

  本发明涉及一种包括钆络合物的磁共振成像（MRI）造影剂，尤其涉及一种 DO3A-氨甲环酸或其酯类化合物，其化学式为 1。 根据本发明可制备 DO3A-氨甲环酸或其酯类化合物，并使用该化合物制备钆络合物。包括根据本发明制备的钆复合物作为活性成分的磁共振成像造影剂与目前市售的造影剂相比具有更高的弛豫性。此外，根据本发明制备的磁共振成像造影剂还具有肝脏特异性造影和血池造影的双重功能。因此，由于本发明的核磁共振成像造影剂（包括钆复合物）满足核磁共振成像造影剂所需的关键特性，因此可广泛用作核磁共振成像造影剂，并能提供比现有造影剂更强的造影效果。
• Organosilicon synthesis of isocyanates: III. Synthesis of aliphatic, carbocyclic, aromatic, and alkylaromatic isocyanatocatboxylic acid esters
  作者：A. V. Lebedev、A. B. Lebedeva、V. D. Sheludyakov、S. N. Ovcharuk、E. A. Kovaleva、O. L. Ustinova

  DOI：10.1134/s1070363206070115

  日期：2006.7

  A series of aminoacid esters was prepared by treating the aminoacid suspensions in ethanol with thionyl chloride. Best conversion of aminoacid esters to corresponding isocyanates was achieved in the case of aromatic and carbocyclic aminoesters by phosgeneation of their N-silyl derivatives, and in the case of aliphatic and alkylaromatic aminoesters by phosgeneation of O-silyl or N,O-bissilylurethanes on their basis. In the last case additional step of esterification of the by-products isocyanatoalkylcarboxylic acid chlorides is reqired after phosgeneation. Unusual generation of cynnamates and intramolecular N -> O-migration of trimethylsilyl group in the solutions of silylated alkylaromatic beta-aminoacid esters were found.